by Truveta staff | Mar 22, 2023 | News
Today, Truveta and Alpine Immune Sciences, Inc. announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory...
by Terry Myerson, CEO | Mar 1, 2023 | News
Today we are excited to announce that we’ve expanded the de-identified data in Truveta Studio to include 28 additional social drivers of health (SDOH) attributes – such as education, income, housing stability, social support, and more – for nearly 80 million...
by Truveta staff | Feb 15, 2023 | News
The United States is one of the most dangerous high-income countries in which to give birth. Nearly every negative maternal health outcome impacts women of color more than white women. This February, in honor of Heart Health Month and Black History Month, Truveta...
by Truveta staff | Dec 7, 2022 | News
We’re proud to share that leaders from a number of our health system members have been named as Modern Healthcare’s 100 Most Influential People In Healthcare in 2022. This list showcases impactful healthcare leaders, nominated by their peers, as the most influential...
by Truveta staff | Nov 18, 2022 | News
Last week, two members of Truveta Research — Dr. Charlotte Baker, DrPH, MPH, CPH, and Dr. Peter Smits, PhD — attended the 150th Annual Meeting of the American Public Health Association (APHA) in Boston. Dr. Peter Smits presented on Truveta Research’s...
by Terry Myerson, CEO | Nov 2, 2022 | News
In just over two years — with amazing teamwork across Truveta and our 25 health system members, and strategic partnerships with customers like Pfizer and Boston Scientific — it is so exciting to announce the availability of Truveta Studio. It is amazing...
